GH insider Kumud Kalia: RSU vesting and small share sale on 09/01/2025

Rhea-AI Filing Summary

Guardant Health director and Chief Information Officer Kumud Kalia reported transactions on Form 4 showing restricted stock units vesting and a small open-market sale. On 09/01/2025, 711 shares were reported as acquired at a $0 price reflecting the vesting of RSUs, leaving 19,211 shares beneficially owned. The filing also shows a disposal of 361 shares on 09/01/2025 at a price of $67.42, reducing reported holdings to 18,850 shares. The RSU award was originally granted in November 2021 and vests quarterly through the three-year schedule that began 09/01/2022.

Positive

• 711 RSU shares vested on 09/01/2025, reflecting scheduled compensation delivery
• Reported beneficial ownership remains substantial at 19,211 shares immediately after the vesting event

Negative

• 361 shares were sold on 09/01/2025 at $67.42, reducing holdings to 18,850 shares

Insights

Securities Analyst

TL;DR: Director sold a small number of shares and had RSUs vest; net holdings declined slightly.

The transactions are routine insider activity: vesting of previously granted restricted stock units produced 711 shares reported as acquired at no cash cost, consistent with the award schedule disclosed in the filing. A contemporaneous sale of 361 shares at $67.42 reduced the director's net ownership by 361 shares to 18,850. The scale of the sale (<2% of post-transaction holdings) appears immaterial to company capitalization.

Corporate Governance Expert

TL;DR: Vesting and a small sale are standard executive compensation events, not indicative of governance issues.

The Form 4 documents an ordinary-course vesting event from a 2021 RSU grant and a partial disposition of shares. The filing includes the RSU vesting schedule (25% vested 09/01/2022, remainder quarterly over three years) which explains the 711-share acquisition. There is no indication of abnormal trading patterns, exceptions, or use of a 10b5-1 plan noted on the face of the form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalia Kumud

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Information Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		M		711	A	$0	19,211	D
Common Stock	09/01/2025		F		361(1)	D	$67.42	18,850	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	09/01/2025		M			711	(2)	(1)	Common Stock	711	$0	0	D

Explanation of Responses:

1. Not applicable for Restricted Stock Units.

2. The restricted stock unit award was granted on November 2, 2021, and vested 25% of the shares subject to such award on September 1, 2022. The remaining 75% of the shares subject to such award vests in equal installments on each quarterly anniversary of September 1, 2022 during the three-year period thereafter.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Kumud Kalia	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Guardant Health (GH) insider Kumud Kalia report on Form 4?

The filing shows 711 shares acquired due to RSU vesting and 361 shares sold at $67.42 on 09/01/2025.

How many shares does Kumud Kalia beneficially own after the reported transactions?

The filing reports 18,850 shares beneficially owned by Kumud Kalia following the sale; 19,211 was the count immediately after the RSU vesting before the sale.

Were the acquired shares a purchase or vesting of restricted stock units for GH insider?

The 711 shares were acquired at a $0 price, indicating they resulted from the vesting of restricted stock units granted on November 2, 2021.

What is the vesting schedule for the RSU award mentioned in the Form 4?

The award vested 25% on 09/01/2022, with the remaining 75% vesting in equal quarterly installments over the subsequent three-year period.

Did the Form 4 indicate use of a 10b5-1 trading plan for these transactions?

The form does not indicate that these transactions were executed pursuant to a 10b5-1 plan; no such box is checked or specified in the provided content.